MYC and bladder transitional cell carcinoma: A recent report by Kluth et al., which also included a large number of samples (2052 UBCs), has revealed a low level MYC copy number gain (MYC/centromere 8 ratio ≥ 2 and ≤ 3) in 6.8% and high-level MYC amplifications (MYC/centromere 8 ratio > 3) in 3.3% of urothelial bladder carcinomas [157].